MARLBOROUGH, Mass., March 24, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data presentations spanning its interventional cardiology, rhythm management and structural heart portfolios, that will be featured at the American College of Cardiology's 65th Annual Scientific Session which will be held in Chicago, April 2-4.

Scheduled abstracts will highlight 'real-world' and clinical trial experiences with technologies developed to treat patients with a range of cardiovascular diseases. Topics to be presented include:

One-year post U.S. Food and Drug Administration (FDA) approval experience using the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device to reduce the risk of stroke in people with non-valvular atrial fibrillation who cannot take warfarin.
Two-year safety and efficacy outcomes with the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System in patients with coronary artery disease from the EVOLVE II trial.

Performance and clinical outcomes of the Lotus™ Transcatheter Aortic Valve Replacement (TAVR) System in patients with severe calcific aortic stenosis from the RESPOND trial.

First-ever pre-clinical data evaluating the Boston Scientific modular therapy approach and communications compatibility between its leadless pacemaker and the EMBLEM™ subcutaneous implantable defibrillator (S-ICD).

Primary results of the NAVIGATE X4 study, the multi-center clinical trial that led to the FDA approval of ACUITY™ X4 Quadripolar left ventricular (LV) leads in February 2016.

"This is a unique congress for us, as we have the opportunity to present new data supporting a number of our key cardiology products which have received FDA approvals since ACC 2015," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "We are also looking forward to unveiling the first data from our leadless pacemaker program, as well as contributing to discussions on the future of transcatheter aortic valve replacement."

Abstracts of Interest (listed chronologically within product categories)

Interventional Cardiology

SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System: Late Clinical Outcomes After Bioabsorbable or Permanent Polymer Everolimus-Eluting Stents: 2-Year Results From the EVOLVE II Randomized Trial: Dean Kereiakes, M.D., will present on Sunday, April 3 at 1:00 PM in the ACC.i2 IC Moderated Poster Theater, South Hall A.

Rhythm Management

ACUITY™ X4 Quadripolar LV leads: Clinical Performance of Physiologically Designed Quadripolar Left Ventricular Pacing Leads: Primary Results from the NAVIGATE X4 Clinical Trial: Suneet Mittal, M.D., will present on Sunday, April 3 at 3:45 PM in the Poster Area, South Hall A1.

Association Viewpoints Homepage